Hear.com Horizon Go IX vs Otofonix Groove

The Hear.com Horizon Go IX is a premium prescription behind-the-ear hearing aid released in 2024, listed at $6,500. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.4/5, ranking #17 among 36 prescription hearing aids tested. This device demonstrates particular strength in speech clarity. Speech in quiet scored a strong 4.0/5, which is +0.72 points above the category average. Speech in noise performance also exceeded the category average by +0.61 points, though at 2.6/5 the absolute score remains mixed—meaning it handles challenging listening environments better than many competitors but still has room for improvement in demanding situations. The most notable limitation is own-voice comfort, scoring 1.8/5—a low result that falls 0.95 points below the category average. Users sensitive to how their own voice sounds may find this particularly noticeable. Feedback handling is strong in absolute terms at 4.4/5, though it sits slightly below the category average by 0.31 points. Music streaming performance is mixed at 2.7/5, essentially matching the category average. At this price point, the Horizon Go IX faces stiff competition. Same-price alternatives like the Phonak Sphere Infinio (5.0/5) and Oticon Intent (4.85/5) deliver higher overall sound performance. Budget-conscious shoppers might also consider options like the Rexton Reach R-Li T80 at Costco, which achieves a higher score at a lower price. The Horizon Go IX is best suited for those prioritizing speech clarity who can accept the own-voice trade-off and prefer the hear.com service model.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.